4 min read
Cleerly: February 27, 2023
Quantification of coronary artery disease (CAD) burden and atherosclerotic plaque type has been shown to be the strongest determinant of future risk of major adverse cardiac events (MACE).1 Until recently, though, there had been no clinically useful...
4 min read
Cleerly: February 13, 2023
Heart disease is the cause of death for 700,000 Americans1 and nearly 17.9 million people worldwide every year.2 While some of these individuals likely had indicators for higher risk, such as high cholesterol or high blood pressure, studies show that up...
4 min read
Cleerly: January 17, 2023
Current methodologies for coronary artery disease (CAD) screening often result in misidentification of low-risk patients and may submit patients to unnecessary and expensive invasive procedures.
Cleerly’s coronary computed tomography angiography...
2 min read
Cleerly: January 17, 2023
Cleerly is making the future of cardiovascular care possible through easy-to-use, clinically proven technology that effortlessly integrates into provider workflows and patient care journeys.
Our personalized care pathway for heart attack prevention...
3 min read
Cleerly: January 17, 2023
Current methodologies for screening for coronary artery disease (CAD) at the primary care provider’s office are often limited. And once heart disease is suspected or identified by these methods, patients must often be referred to a specialist for...
2 min read
Cleerly: January 10, 2023
Cleerly makes early detection of heart disease risk possible through our AI-enabled analysis of coronary computed tomography angiography (CCTA) imaging that guides physicians towards creating personalized and preventive treatment plans for patients. To...
3 min read
Cleerly: October 18, 2022
Half of patients who have a heart attack don't show symptoms prior to their event. A new standard of precision care that emphasizes comprehensive evaluation of atherosclerotic plaque for guiding personalized treatment and tracking heart disease over time...
3 min read
James K. Min, MD, FACC, FESC, MSCCT, Founder & CEO of Cleerly: September 19, 2022
Myocardial perfusion, also known as a "stress test", is today's go-to-method for detecting coronary artery disease - despite limited performance.
7 min read
James K. Min, MD, FACC, FESC, MSCCT, Founder & CEO of Cleerly: August 1, 2022
The current approach to cardiovascular care is flawed for two reasons. One is the lack of a disease-based care paradigm with a focus on actual heart disease–atherosclerosis– in lieu of an emphasis on symptom-driven care that identifies only late-stage...
3 min read
Last week, our team at Cleerly had the opportunity to take part in a gathering of impassioned cardiac computed tomography (CT) leaders at the Society of Cardiovascular Computed Tomography (SCCT) Annual Scientific Meeting in Las Vegas. As the former...
